Modiodal

Selected form

Modafinil

Method of action: Psychoanaleptics

Treatment option: Wakefulness, Cataplexy, Narcolepsy, Excessive Sleepiness

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modiodal

Quick Facts

Modiodal is a prescription-only medication whose pharmacological activity is derived from its single active ingredient, the chemical substance Modafinil (INN). The compound is classified as a wakefulness-promoting agent (Eugeroic), supplied as tablets, and is a synthetic compound intended to promote alertness and vigilance.

What is Modiodal and How is it Classified?

Modiodal is a brand name for the active substance Modafinil, which is a synthetic derivative designed for oral administration in tablet form. This preparation is manufactured and distributed primarily across markets in Europe and Asia, positioning it as a distinct, fixed-dose formulation. The compound is chemically distinct and is clinically recognized for its targeted support of central nervous system function. The pharmaceutical identity of Modiodal is defined by its use of Modafinil as the sole active component.

Its Unique Pharmacological Type

Modafinil is formally classified as a wakefulness-promoting agent, distinguishing it from traditional central nervous system (CNS) stimulants such as amphetamine-based products. This classification as an eugeroic indicates its general purpose is to promote and sustain a functional state of alertness and vigilance. Modafinil is noted to have an atypical mechanism of action compared to older stimulant classes. Pharmacological evidence indicates that Modafinil achieves its effect through a more selective influence on specific brain regions, acting as a weak inhibitor of dopamine reuptake, which facilitates wakefulness without inducing the high level of generalized stimulation typically associated with less selective agents.

Composition and Pharmaceutical Form

The pharmaceutical preparation of Modiodal ensures effective delivery of the active ingredient through oral administration. The final composition consists solely of the Modafinil active drug, complemented by various solid oral excipients like lactose and microcrystalline cellulose, which are necessary for the tablet’s structure and disintegration. This preparation is designed to consistently deliver the single active ingredient for its intended wakefulness-promoting agent function.

What side effects are possible with Modiodal?

Possible Side Effects and Safety Information

The official safety profile for Modiodal (Modafinil) is classified by governmental regulatory authorities based on the frequency and the System-Organ Class (SOC) affected. Adverse reactions are grouped by severity and the body system where the effects are observed, such as Psychiatric, Nervous System, and Cardiovascular disorders.

Frequency Classification of Adverse Reactions

Classification	Examples of Reactions
Very Common (ge 10%)	Headache, Nausea
Common (1%-10%)	Nervousness, Insomnia, Anxiety, Diarrhea, Dizziness, Hypertension, Palpitations, and Tachycardia

Serious Adverse Reactions and Safety Constraints

Official regulatory documentation highlights the risk of several serious adverse reactions. These include Serious Rash, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Reports also document the occurrence of Multi-organ Hypersensitivity Reactions and severe Psychiatric Symptoms (e.g., suicidal ideation and mania).

Some of these reactions, including serious rash, have been reported in close temporal association with the initiation of treatment, often within the first few weeks.

Safety restrictions exist for specific populations and conditions. Modiodal is formally Contraindicated in individuals with uncontrolled moderate to severe hypertension or cardiac arrhythmias. For patients with Severe Hepatic Impairment, a dose reduction is formally required. Furthermore, the use of the medicine is generally not recommended for the pediatric population.

Overdose and Emergency Response

Official Regulatory Information for Modiodal Overdose

The official overdose profile for Modiodal (Modafinil) is defined by documented manifestations across the central nervous and cardiovascular systems. These statements reflect information found in authoritative regulatory documents.

Documented Manifestations

Overdose symptoms, which have been reported in cases involving Modiodal alone or with other substances, primarily include CNS excitation and psychiatric effects. These manifestations can involve insomnia, agitation, restlessness, confusion, disorientation, and hallucination. Severe psychiatric outcomes such as the onset of psychosis or mania are also documented. Cardiovascular effects reported in regulatory sources include tachycardia (fast heart rate), bradycardia (slow heart rate), hypertension, and the potential for cardiac arrhythmias. Gastrointestinal effects such as nausea and diarrhea are also listed. Accidental ingestion/overdose cases have been reported in children, where the clinical manifestations were similar to those observed in adults.

Mandated Emergency Action and Management

In the event of a suspected overdose, regulatory guidance mandates that patients seek immediate medical attention by contacting emergency services or a Poison Control helpline. Urgent medical help is required for severe symptoms such as profound confusion, hallucinations, collapse, seizure, or a significantly fast or abnormal heart rate.

Management is focused on symptomatic and supportive care, as no specific antidote is known to exist. This supportive approach includes continuous monitoring of vital signs and managing acute symptoms like severe agitation.

Therapeutic Uses of Modiodal

What Modiodal Treats: Main Uses and Benefits

Modiodal is considered relevant for supporting wakefulness in adults who experience persistent excessive sleepiness related to specific medical conditions. It is indicated for the symptomatic management of Narcolepsy, residual sleepiness associated with Obstructive Sleep Apnea (OSA), and Shift Work Sleep Disorder (SWSD). This agent is applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning.

The goal is supporting sustained alertness, which may help patients cope more steadily with the overall symptom load of hypersomnolence. The medication is relevant for addressing symptoms related to heightened physiological activity and may provide support that helps ease the symptom burden during difficult episodes.

In clinical scenarios, it is used to support alertness during scheduled night or rotating shifts, or to help patients with OSA maintain a sense of stability when sleepiness is still noticeable despite primary treatment.

Quick Fact: Relief for Excessive Daytime Sleepiness

Modiodal is commonly used to help manage the symptom clusters of overwhelming sleepiness and impaired vigilance during waking hours, which may assist with maintaining a sense of stability across chronic neurological or circadian rhythm conditions.

Eligibility and Restrictions for Use

Official Population Eligibility Rules

The eligibility profile for Modiodal (Modafinil) is strictly defined by regulatory authorities and is determined by age, physiological status, and pre-existing conditions. The medication is indicated for use only in adults (aged 18 and older) who experience excessive sleepiness related to Narcolepsy, Obstructive Sleep Apnea, or Shift Work Disorder.

Absolute Contraindications

Use of Modiodal is absolutely contraindicated in patients with a known hypersensitivity to modafinil or armodafinil. It is also prohibited for individuals with pre-existing uncontrolled moderate to severe hypertension or cardiac arrhythmias. Use is contraindicated during pregnancy, and women of childbearing potential must use effective non-hormonal contraception during treatment and for two months after stopping.

Restricted and Non-Recommended Use

Modiodal is not recommended for the pediatric population (under 18) due to safety concerns. Older adults (over 65) should commence treatment at a lower dose. Patients with severe hepatic impairment (liver disease) must have their dosage reduced by one-half. Caution is required for those with severe renal impairment or a history of certain psychiatric disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Modiodal’s official interaction profile is defined by its pharmacokinetic influence on the clearance of co-administered medicinal products, primarily through the Cytochrome P450 enzyme system, where it acts as both a metabolic inducer and an inhibitor.

Interactions Decreasing Exposure (CYP3A4/5 Induction)

Modiodal is documented as a potent inducer of the CYP3A4/5 enzyme. This action accelerates the metabolism and significantly reduces the systemic exposure of medicines that are substrates for these enzymes. This effect is clinically significant for steroidal hormonal contraceptives, which can have their effectiveness reduced. Other affected medicines include Cyclosporine and certain benzodiazepines. The official labeling mandates that patients using hormonal contraception must switch to an alternative non-hormonal method during treatment and for two months after stopping Modiodal.

Interactions Increasing Exposure (CYP2C19 Inhibition)

Conversely, Modiodal acts as an inhibitor of the CYP2C19 enzyme. This reduces the clearance of certain co-administered drugs, potentially leading to increased plasma concentrations. Examples of medicines affected include Omeprazole, Phenytoin, and certain tricyclic antidepressants.

Pharmacodynamic and Substance Interactions

Official regulatory information advises against co-administration with alcohol or other CNS stimulants due to the potential for additive pharmacodynamic effects on cardiovascular parameters like heart rate and blood pressure.

Mechanism of Action

How Modiodal Works

The mechanism of action of Modafinil (Modiodal) is complex and involves multiple, coordinated neurochemical pathways that target brain systems regulating arousal.

Selective Dopamine Transporter Inhibition

This mechanism addresses the drug’s primary molecular interaction: binding to the Dopamine Transporter (DAT). Modafinil acts as a weak inhibitor of this transporter, blocking the reuptake of dopamine and increasing its concentration in the synaptic space. This action modulates the dopaminergic system, altering the dopaminergic signaling balance.

Modulation of Arousal-Peptide Systems

Modafinil also exerts indirect influence on key vigilance pathways, notably the Histaminergic and Orexin (Hypocretin) systems. The drug promotes the release of these wakefulness-regulating mediators by reducing the inhibitory tone of GABAergic neurons onto them. This disinhibition cascade functions as a key component in the regulation of the central arousal state.

Causal Chain to Sustained CNS Arousal

The convergence of increased dopamine tone and enhanced orexin/histamine signaling concentrates neural activity in brain regions that govern arousal. This cascade modifies the balance of inhibitory and excitatory inputs in arousal centers, shifting the physiological state toward sustained central nervous system arousal.

Dosage and Administration Information

How Modiodal is Used

Modiodal (modafinil) is an orally administered medication supplied in tablet form, commonly available in 100 mg and 200 mg strengths. The medicine is taken for its wakefulness-promoting action according to specific dosage and timing instructions.

Dosing and Frequency Patterns

The standard starting dose for adults is 200 mg taken once per day. This regimen is applied across indications such as Narcolepsy and excessive sleepiness associated with Obstructive Sleep Apnea (OSA). The total daily dose may be increased up to a maximum of 400 mg per day, which may be administered as a single dose or divided into two doses (morning and noon).

Narcolepsy and OSA: The dose is typically taken once daily in the morning.
Shift Work Sleep Disorder (SWSD): The dose is taken once daily approximately one hour prior to the start of the scheduled work shift.

Administration Conditions

The tablets should be swallowed whole and may be taken with or without food; food does not affect the overall amount of medicine absorbed. Treatment is typically initiated under the supervision of a physician with appropriate knowledge of the condition being managed.

Population-Specific Adjustments

Dose modifications apply for certain populations. For patients with severe hepatic impairment, the dosage is reduced by one-half of the usual dose, meaning a maximum daily dose of 100 mg. For older adults (over 65), a lower initial dose is generally advised. Use in pediatric patients (under 18 years) is not recommended, as safety and efficacy have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Modiodal

Evidence for Use in Narcolepsy

Clinical evaluation of Modiodal was studied for its role in managing excessive daytime sleepiness (EDS) associated with narcolepsy. The core research was evaluated using multiple short-term, double-blind trials designed with a comparison against an inactive substance (placebo). Researchers monitored the ability to sustain wakefulness using laboratory tests like the Maintenance of Wakefulness Test (MWT) and assessed subjective sleepiness using scales like the Epworth Sleepiness Scale (ESS). Findings describe patterns observed in the studies where patterns related to measurements on these alertness and sleepiness test scores were observed across the short trial duration. What remains uncertain is the extent of research that explored outcomes related to other primary symptoms of narcolepsy, such as cataplexy, and the duration of controlled follow-up remains limited for assessing long-term stability.

Evidence for Use in Residual Sleepiness from Obstructive Sleep Apnea (OSA)

Modiodal was studied for use as an adjunct (supplementary) treatment for people with OSA who experience residual EDS despite receiving primary therapy, such as CPAP. The core research used short-term, randomized, placebo-controlled trials. Studies examined outcomes related to systemic or functional imbalance by measuring objective wakefulness (MWT) and subjective sleepiness (ESS). Findings indicate that when used alongside primary OSA treatment, studies reported measurements of changes in sleepiness scores. The evidence gathered indicates that this agent was studied for use only as an adjunct treatment, and the research did not focus on outcomes related to the underlying respiratory episodes of OSA.

Evidence for Use in Shift Work Sleep Disorder (SWSD)

Research examined Modiodal in adults diagnosed with SWSD, a condition where symptoms may vary in intensity due to night or rotating work shifts. The studies were mid-term, placebo-controlled trials. Researchers monitored objective alertness and performance by using standardized tests, such as the Psychomotor Vigilance Test (PVT). Research highlights patterns observed in the studies related to objective performance and subjective sleepiness scores compared to placebo during the working hours. The follow-up durations were limited compared to the chronic nature of SWSD, and some residual sleepiness and performance impairment were still measured in the observed populations.

What is Still Uncertain About the Modiodal Evidence Base

The most controlled trials are typically short-term, meaning long-term effects are not fully established by the same rigorous standards as the initial findings. The research was observed in a relatively narrow set of populations, and data for certain groups remain insufficient for drawing definitive conclusions. Scientific sources often describe areas for further research to fully characterize the sustained response and address these limitations.

Key Studies & References

European Medicines Agency (EMA) Recommendation: restricting the use of modafinil (Withdrawal of OSA and SWSD indications in EU)

Frequently Asked Questions (FAQ)

Common questions about Modiodal (FAQ)

Q: Does Modiodal cure Narcolepsy, or does it only treat the symptoms?

According to official drug information, this medication does not provide a cure for sleep disorders such as Narcolepsy. Its purpose is to help manage the symptoms by promoting wakefulness and is prescribed to address the excessive sleepiness associated with these conditions.

Q: How quickly does Modiodal start working after taking a dose?

Regulatory documents state that after taking the tablets, the concentration of the medicine in the blood typically reaches its peak within two to four hours. This time frame reflects when the medicine’s concentration in the body is highest.

Q: What is the difference between Modiodal and other traditional CNS stimulants?

Modiodal (modafinil) is officially categorized as a wakefulness-promoting agent, distinguishing it from traditional central nervous system (CNS) stimulants. It is classified as a Schedule IV controlled substance, while many traditional stimulants are classified in Schedule II. This difference reflects the regulatory assessment of potential for abuse and dependence.

Q: Can Modiodal be used alone to treat OSA, or is it an add-on treatment?

For Obstructive Sleep Apnea (OSA), official labeling states that this medicine is intended to be used only as an add-on or supplementary treatment. Official labeling indicates it is not intended to be used as a replacement for primary OSA treatments, such as breathing devices (like CPAP).

Q: What is the half-life of Modiodal?

The half-life of a drug is the time it takes for the amount of active substance in the body to be reduced by half. According to the drug’s pharmacokinetics data, the effective half-life of modafinil after multiple doses is approximately 15 hours.

Q: Can Modiodal cause weight loss or affect my appetite?

Official product information lists decreased appetite as a common side effect of modafinil. Changes in appetite may be observed while taking the medication.

Q: What should I do if I miss a dose of Modiodal?

If a dose is missed, regulatory patient information generally advises against taking it if it is close to bedtime or if you do not plan to stay awake for a prolonged period. The guidance suggests skipping the missed dose instead of taking extra medicine to compensate.

Q: How long does it take for Modiodal to clear out of my system after I stop taking it?

Based on pharmacokinetics studies, most of the administered drug-related material is recovered in the urine within 11 days after the last dose is taken. This figure indicates the approximate time frame required for the body to eliminate the substance.

Q: Is Modiodal a controlled substance?

Yes, Modiodal (modafinil) is classified as a Schedule IV controlled substance in the US. This classification is given because the medication has a recognized potential for abuse and dependence.

Q: Is there a risk of dependence or withdrawal symptoms with Modiodal?

The medicine is classified as a controlled substance due to its recognized potential for abuse and dependence. While one controlled trial did not report withdrawal symptoms after nine weeks of use, patients who stop taking the medicine may experience a return of their original excessive sleepiness.

How should Modiodal be stored and disposed of?

How to Store and Dispose of Modiodal

Modiodal (Modafinil) tablets must be stored according to official regulatory labeling to ensure product stability and safety. The required conditions are strictly defined.

Storage Requirements

Modiodal must be stored at controlled room temperature (20 C to 25 C) and protected from excess heat and moisture. Storage in the original, tightly closed container with a child-resistant closure is mandatory. The medicine must be kept out of the sight and reach of children at all times. Certain packaging, such as HDPE bottles, may have an official 4-month limit for use once opened.

Disposal Instructions

Disposal of unused or expired Modiodal should primarily be done through a drug take-back program. If a take-back program is unavailable, the official procedure is to mix the tablets with an undesirable substance (such as dirt or cat litter) and place the mixture in a sealed container before disposal in the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.